Dashboard/AJOONI

AJOONI

FAIRLY_VALUED

Ajooni Biotech Limited

Pharma · NSE

↓ 10.9% vs fair value

52W Low

₹4

+14.9% from low

52W High

₹7

-38.2% from high

News sentiment (0 articles)

0 bull0 neutral0 bear

Valuation Gauge

FAIRLY_VALUED-10.9% Margin of Safety

OVERVALUEDFAIRLY VALUEDUNDERVALUED

Current Price

₹4

Fair Value

₹4

Fair Value Analysis

₹4

Based on earnings growth potential for Pharma sector companies | Sector-cheap: P/E at 12th percentile vs sector peers. | CAUTION: ROCE declining (latest 4.4%) — returns on capital are falling; verify this isn't a value trap. | Growth capped at 6.3% (ROE 5.5%×1.15) — historical CAGR exceeds sustainable rate or COVID period unverifiable.

Low confidence

Growth Valuation

100% weight

₹4

Price vs Market

AJOONI

Nifty 50

Shareholding Pattern

Stock Health Score

Solid Fundamentals

6.8 / 10

Profitability

6/10

ROE of 5.5% is below the Pharma sector benchmark of 18%

Debt & Leverage

10/10

D/E ratio of 0.1x is well within the Pharma sector norm of 0.8x — strong balance sheet

Valuation vs Peers

10/10

P/E of 14.1x trades at a 66% discount to Pharma sector median (42x) — attractively valued

Cash Flow

1/10

Negative FCF of ₹-20 Cr — company is consuming more cash than it generates

Earnings Growth

10/10

5yr EPS CAGR of 47.6% is well above the Pharma sector average of 15.3% — strong growth

Dividend

4/10

No dividend — typical for growth-stage companies

Sentiment Trend — Last 30 Days

Historical Returns

Key Ratios & Growth

FCF Yield

-51.9%

Free cash flow / market cap

Revenue Growth (YoY)

+72.6%

Year-on-year revenue change

Profit Growth (YoY)

+126.0%

Year-on-year PAT change

Operating Cash Flow

₹-18 Cr

TTM cash from operations

Key Financials

EPS (TTM)

₹0.3

P/E Ratio

14.1x

P/B Ratio

0.8x

ROE

5.5%

ROCE

5.1%

Debt / Equity

0.11x

Beta

0.44

Div Yield

—

FCF (Cr)

₹-20 Cr

Revenue (Cr)

₹115 Cr

EPS Growth 5Y

47.6%

Mkt Cap (Cr)

₹70 Cr

52W High

₹6.6

52W Low

₹3.6

Book Value/Share

₹5.4

Financial History

Period	Revenue	Op Profit	OPM%	PAT	EPS
TTM	₹151 Cr	₹6 Cr	4.0%	₹5 Cr	₹0.29
2025-03-31	₹115 Cr	₹4 Cr	3.0%	₹3 Cr	₹0.20
2024-03-31	₹80 Cr	₹2 Cr	3.0%	₹2 Cr	₹0.12
2023-03-31	₹74 Cr	₹3 Cr	4.0%	₹1 Cr	₹0.06
2022-03-31	₹74 Cr	₹3 Cr	4.0%	₹1 Cr	₹0.05
2021-03-31	₹51 Cr	₹2 Cr	3.0%	₹0 Cr	₹0.02
2020-03-31	₹40 Cr	₹1 Cr	3.0%	₹0 Cr	₹0.02
2019-03-31	₹40 Cr	₹1 Cr	2.0%	₹0 Cr	₹0.03
2018-03-31	₹42 Cr	₹1 Cr	2.0%	₹0 Cr	₹0.03
2017-03-31	₹29 Cr	₹1 Cr	2.0%	₹0 Cr	₹0.36
2016-03-31	₹13 Cr	₹0 Cr	2.0%	₹0 Cr	₹0.18
2015-03-31	₹7 Cr	₹0 Cr	2.0%	₹0 Cr	₹0.12
2014-03-31	₹1 Cr	₹0 Cr	2.0%	₹0 Cr	₹0.02

Compounded Growth Rates

Sales Growth

3Y+26.8%

5Y+24.2%

10Y+27.8%

Profit Growth

3Y+71.0%

5Y—

10Y—

EPS Growth

3Y+69.1%

5Y+70.7%

10Y+4.9%

Peer Comparison

Pharma

Stock	Price	Fair Value	MoS%	P/E	ROE	Signal
PAR Par Drugs And Chemicals Limited	₹86	₹469.7	+81.7%	7.3	15.4%	FAIRLY_VALUED
IOLCP IOL Chemicals and Pharmaceuticals Limited	₹79.5	₹237.8	+66.6%	19.6	5.2%	FAIRLY_VALUED
KILITCH Kilitch Drugs (India) Limited	₹132.7	₹321	+58.7%	17.7	9.4%	UNDERVALUED
BALPHARMA Bal Pharma Limited	₹69	₹147.5	+53.2%	12.8	12.6%	FAIRLY_VALUED
ZYDUSLIFE Zydus Lifesciences	₹868	₹1,502.2	+42.2%	17.6	19.9%	UNDERVALUED
NATCOPHARM Natco Pharma	₹1,030	₹1,597	+35.5%	11.8	18.0%	UNDERVALUED
JAGSNPHARM Jagsonpal Pharmaceuticals Limited	₹190.6	₹275.2	+30.7%	30.8	20.1%	UNDERVALUED
LUPIN Lupin	₹2,280	₹3,112	+26.7%	22.4	23.8%	UNDERVALUED